Back to top
more

Inozyme Pharma (INZY)

(Delayed Data from NSDQ)

$4.85 USD

4.85
222,160

+0.12 (2.54%)

Updated Jun 5, 2024 04:00 PM ET

After-Market: $4.85 0.00 (0.00%) 6:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for INZY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Inozyme Pharma, Inc. [INZY]

Reports for Purchase

Showing records 21 - 40 ( 71 total )

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

08/08/2023

Company Report

Pages: 8

2Q23 Results; Data Readouts For INZ-701 in Adults With ENPP1 Deficiency and ABCC6 Deficiency Expected in September

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

08/08/2023

Company Report

Pages: 5

INZY with More Wins Around the Corner

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

08/04/2023

Company Report

Pages: 7

Model Update Following Capital Raise

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

07/26/2023

Company Report

Pages: 8

Pivotal INZ-701 Protocol and Endpoints Established; Pediatric Study Expected to Begin in October

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

07/26/2023

Company Report

Pages: 6

INZ-701 on Full ENERGY

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

06/27/2023

Daily Note

Pages: 3

First Patient Dosed in Phase 1b Study of INZ-701 in Infants With ENPP1 Deficiency

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

05/10/2023

Company Report

Pages: 8

1Q23 Results; Upcoming Milestones For INZ-701 Remain On-Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

05/09/2023

Company Report

Pages: 5

Down With ENPP1? Yeah You Know INZY

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

03/23/2023

Company Report

Pages: 8

4Q22 Results; More INZ-701 Data Expected in 3Q23; New CEO Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

03/22/2023

Company Report

Pages: 5

Pivoting Towards the Next Stage of Development

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

03/12/2023

Industry Report

Pages: 12

As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/01/2023

Industry Report

Pages: 16

The Wedbush Monthly Check-Up: March 2023

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

02/17/2023

Company Report

Pages: 8

Top-Line INZ-701 Results Announced For Both ABCC6 Deficiency and ENPP1 Deficiency

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

02/16/2023

Company Report

Pages: 8

Putting More Meat on the Bones of ''701''s Data

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

02/06/2023

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

01/30/2023

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

01/30/2023

Daily Note

Pages: 5

INZ-701 Prepares for a Double Header

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

01/10/2023

Daily Note

Pages: 3

2022 Progress; Investor and Analyst Event in February

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

12/08/2022

Daily Note

Pages: 3

Update on INZ-701 Trials; Phase 1 Top-Line Data Projected for Early 1Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Inozyme Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

11/11/2022

Company Report

Pages: 8

3Q22 Results; Top-Line Data From Phase 1/2 Clinical Trial of INZ-701 in ENPP1 Deficiency Anticipated Later This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party